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Objective: From 2006 to 2014, more than 800 patients had received robotic-assisted laparoscopic radical
prostatectomy (RaLRP) at our hospital. Based on our single-center experience, the procedure has been
found to be safe and feasible among these patients with regard to oncologic control and functional
outcome. We compared these patients with those who received radiotherapy (RT; all aged > 75 years)
and attempted to clarify whether there is any beneﬁt with regard to oncologic control, functional
outcome, and comorbidity.
Materials and methods: We performed a retrospective review of 188 prostate cancer patients aged > 75
years in our hospital over a period of 5 years (79 patients had received RaLRP and 109 patients had
received RT). Cancer control result was determined based on the 1-year biochemical recurrence (BCR)
rate. In the surgical group, BCR was deﬁned as a sustained increase, on two separate occasions, in the
serum total prostate-speciﬁc antigen (PSA; >0.2 ng/mL) level, whereas in the RT group it was deﬁned as
an increase in the PSA level of 2 ng/mL above the nadir PSA level. Functional results were determined
based on the continence rate, clinical condition of low urinary tract symptoms, and other complications.
Results: Regarding oncologic control (1-year BCR rate), there was no difference between the two groups
(RaLRP vs. RT: 20.93% vs. 23.95%, p ¼ 0.6950). The 1-year continence rate in the RaLRP group was 90.69%.
By contrast, 80.20% of the patients in the RT group suffered from low urinary tract symptoms requiring
medication and 21.87% of the patients suffered from bladder outlet obstruction, which may require other
interventions; approximately 28.12% of the patients suffered from radiation cystitis and 12.5% of patients
suffered from radiation proctitis.
Conclusion: Our analysis shows that there is no difference in oncologic outcome between the two
groups; however, there is still a lack of reliable evidence owing to the short duration of follow up. It was
also difﬁcult to conﬁrm whether there are any beneﬁts in functional outcomes between these two
procedures. However, despite the old age of the patients, RaLRP could offer a good 1-year continence
outcome.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Radical prostatectomy seems to be the most common treatment
for clinically localized, high-risk prostate cancer, with reports
indicating better overall and cancer-speciﬁc mortality in this group
of patients.1 However, traditionally, radical prostatectomy is rarelyment of Surgery, Number 160,
General Hospital, Taichung
ociation. Published by Elsevier Taoffered to patients over the age of 70 years due to concerns related
to a short life expectancy, poor functional outcomes, and higher
biochemical failure rates.2 Radiotherapy (RT) with or without
androgen-deprivation therapy (ADT) seems to be the treatment of
choice among this group of patients. After its introduction in 2000,
the widespread use of robotic-assisted laparoscopic radical pros-
tatectomy (RaLRP) becamemore common. The procedure appeared
to have reduced surgical morbidity and lowered the risk of a pos-
itive surgical margin, which may in turn reduce cancer recurrence
rates and the need for further treatment.3 Older patients typically
presented with higher prostate-speciﬁc antigen (PSA) levels andiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Treatment option and patient characteristics.
Treatment options p
Radiotherapy
(n ¼ 96)
RaLRP
(n ¼ 43)
n % n %
Age a <0.001*
Median (IQR) 79.50 (77e82) 76.00 (75e78)
PSA initial
diagnosis a
0.0547
Median (IQR) 15.67 (9.76e29.08) 12.24 (7.5e22.21)
Clinical stage 0.7551
T1e2a 28 (29.16) 16 (37.21)
T2b 21 (21.87) 9 (20.93)
>T2c 47 (48.95) 18 (41.86)
D'amico risk 0.0860
Low 9 (9.37) 8 (18.60)
Intermediate 21 (21.87) 13 (30.23)
High 66 (68.75) 22 (51.16)
Biopsy Gleason
score
0.2605
<7 36 (41.86) 18 (41.86)
7 29 (30.20) 17 (39.53)
>7 31 (32.29) 8 (18.60)
* p < 0.05.
IQR¼ interquartile range; PSA¼ prostate-speciﬁc antigen; RaLRP¼ robotic-assisted
laparoscopic radical prostatectomy.
a ManneWhitney or Chi-square test.
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biochemical recurrence (BCR)-free outcomes.4,5
Robotic-assisted radical prostatectomy offers excellent short-
term trifecta outcomes (continence, potency, and oncology) when
performed by an experienced surgeon.6 As our single-center
experience showed, RaLRP is a safe and feasible procedure in
high-risk prostate cancer patients.7 Therefore, it is worth exam-
ining whether or not it would offer any beneﬁts to this group of
patients in contrast to RT; to date, no studies have made such a
comparison.
We attempted to compare the two methods (RaLRP and RT) and
to clarify whether there was in fact any beneﬁt between these
procedures regarding oncologic control and functional outcome.
2. Materials and methods
2.1. Deﬁnition
Patients were categorized into the low, intermediate, and high-
risk groups, according to the D'amico criteria.8 Transrectal ultra-
sound prostate biopsy was performed on all patients to collect
samples of prostate tissues before the operation. The tissues were
examined and the Gleason score of the patients was recorded.
Digital rectal examination was performed for clinical staging and
magnetic resonance images were reviewed before treatment.
Oncologic control was determined based on the 1-year BCR rate.
In the surgical group, there was no signiﬁcant difference between
perioperative and postoperative measurements. BCR was deﬁned
as a sustained increase, on two separate occasions, of the serum
total PSA level (>0.2 ng/mL). If the PSA level did not decrease to
0.2 ng/mL after the operation, treatment failure is indicated, sug-
gesting recurrence (i.e., biochemical failure).
In the RT group, BCR was deﬁned as an increase of the PSA level
of2 ng/mL above the nadir PSA level. However, if the PSA level did
not reach a nadir level following treatment, the patients were
categorized under the biochemical failure group.
The Chi-square test was used to compare the group character-
istics, with critical values and statistical signiﬁcance at p < 0.05.
2.2. Study population
From June 2007 to December 2013, we reviewed patients who
had received treatment at the Taichung Veteran General Hospital,
Taiwan. A total of 188 patients with prostate cancer aged >75 years
were identiﬁed. Of these 188 patients, 79 had received RaLRP and
43 patients who had been followed up for >1 year met our inclu-
sion criteria. There were a total of 109 patients in the RT group;
however, 13 patients were lost to follow up after the intervention.
Thus, 96 patients met the study inclusion criteria in this group.
According to the D'amico criteria, patients were classiﬁed into the
following subgroups: low, intermediate, and high risk.8 Tumors
were classiﬁed according to the 2002 American Joint Committee on
Cancer classiﬁcation,9 and the Gleason systemwas used for grading.
2.3. Surgical treatment
The patients were operated on using a conventional four-arm da
Vinci robotic system (Intuitive Surgical, Sunnyvale, CA, USA) as
previously described.7,10,11 The neurovascular bundle was pre-
served due to the risk of cancer according to the Gleason score of
tumor and clinical staging. An athermal intrafascial dissection was
performed to preserve the neurovascular bundle.12,13 Posterior
musculofascial reconstruction was carried out and the pubopro-
static ligaments, arcus tendineus, and puboperinealis muscle were
spared to improve continence.13 Two 14-cm long 3-0 MONOCRYLcontinuous sutures (Ethicon, INC 2007) were used for ure-
throvesical anastomosis.14 Additional details on this procedure
were described in our previous single-center experience.10,11
BCR was deﬁned as two consecutive PSA levels >0.2 ng/mL after
RaLRP Salvage management, which included either hormone
therapy or salvage RT, was initiated when BCR was impressed. The
1-year BCR rate in these patients was calculated, and surgical
complications were also described. The functional results were
determined based on the continence rate, and included only stress
urinary incontinence requiring medication or one safety pad or less
per day.
2.4. Radiotherapy
All patients in the RT group received intensity-modulated RT.
High doses (>70 Gy) were used and the daily dose was >180 cGy.
Hormone therapy was used in all patients with a high-risk prostate
cancer in conjunction with RT, along with gonadotropin-releasing
hormone agonist and combined androgen blockade. The PSA level
was monitored after RT and the nadir level was recorded. BCR was
calculated according to the deﬁnition of nadir þ 2 ng/mL. If
biochemical failure occurred, we considered salvage management
such as hormone therapy or if castration-resistant prostate cancer
was impressed, further chemotherapywas applied. Furthermore,10
patients with biochemical failure with persistent bladder outlet
obstruction received salvage radical prostatectomy.
3. Results
Table 1 presents the patient characteristics. A total of 43 patients
in the surgical group and 96 patients in the RT group were included
in this study. Patients who received radiation were signiﬁcantly
older than those who received surgery (median age, 79.50 years vs.
76.00 years; p < 0.001). There was no difference in the PSA level at
the initial diagnosis between the two groups (15.67 ng/mL vs.
12.24 ng/mL, p ¼ 0.0547). Tumor staging and risk category were
deﬁned according to the National Comprehensive Cancer Network
Table 2
Perioperative and postoperative characteristics.
All (n ¼ 43) Low (n ¼ 8) Intermediate (n ¼ 13) High (n ¼ 22) p
n % n % n % n %
Positive surgical margin 22 51.16 2 25.00 4 30.76 16 72.72 0.0650
Seminal vesicle 15 34.88 1 12.5 3 23.07 11 50.00 0.1618
Lymph node involvement 2 4.65 0 0.00 1 7.69 1 4.54 0.6121
Perineural invasion 25 58.13 2 25.00 5 38.46 18 81.81 0.0001**
Angiolymphatic invasion 14 32.55 0 0.00 4 30.76 10 45.45 0.1413
Blood loss (mean ± SD) 142.32 ± 176.59 110.77 ± 143.61 202.65 ± 281.75 127.32 ± 120.54 0.2017
Time to PSA failure (mean ± SD) 24.18 ±20.84 24.92 ±22.09 30.00 ±18.55 21.54 ±21.31 0.0793
Follow-up duration (mean ± SD) 31.99 ±22.97 34.38 ±25.91 38.29 ±23.11 28.61 ±21.86 0.1018
1-mo continence rate 28 65.11 5 62.5 9 69.23 13 59.09 0.9514
3-mo continence rate 36 83.72 7 87.5 11 84.61 18 81.81 0.9857
1-y continence rate 39 90.69 7 87.5 13 100 19 86.36 0.1842
KruskaleWallis test or Chi-square test.
* p < 0.05; ** p < 0.01.
PSA ¼ prostate-speciﬁc antigen; SD ¼ standard deviation.
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tients were classiﬁed in the low-risk group, 21 (21.87%) patients in
the intermediate-risk group, and 66 (68.75%) patients in the high-
risk group. In the surgical group, eight (18.60%) patients were
classiﬁed in the low-risk group, 13 (30.23%) patients in the
intermediate-risk group, and 22 (51.16%) patients in the high-risk
group. There was no signiﬁcant difference between the two
groups (p ¼ 0.0860). The Gleason score was calculated and there
was no signiﬁcant difference between the two groups (p ¼ 0.2605).
Moreover, all high-risk patients or those with advanced clinical
stages in the RT group received ADT during the treatment period.
All patients were followed up for at least 1 year.
The perioperative and postoperative conditions are presented in
Table 2. The rate of positive surgical margin was 51.16%. The 1-
month, 3-month, and 1-year continence rates were 65.11%,
83.72%, and 90.69%, respectively.
The 1-year BCR rate was set as the primary end point (Table 3).
In the RT group, 23/96 (23.95%) patients experienced BCR: ﬁve
patients with intermediate risk (23.80%) and 18 patients with high
risk (27.27%). By contrast, nine (20.93%) patients suffered from BCR
in the surgical group; six of these were high-risk patients and one
patient was in the intermediate-risk category. Among all patients
there was no signiﬁcant decrease in the 1-year BCR (p ¼ 0.5623). In
addition, no signiﬁcant difference was observed when patients
were analyzed based on risk levels (low risk: 0.00% vs. 25.00%,Table 3
Oncology outcome for the two groups.
Treatment option p
RT (n ¼ 96) RaLRP (n ¼ 43)
n % n %
1-y BCR
Low a 0 (0.00) 2 (25.00) 0.2059
Intermediate a 5 (23.80) 1 (7.69) 0.2309
High 18 (27.27) 6 (27.27) 0.8428
Total 23 (23.95) 9 (20.93) 0.6950
Bone metastasis
Low 0 (0.00) 0 (0.00) d
Intermediate 0 (0.00) 0 (0.00) d
High a 6 (9.09) 0 (0.00) 0.1429
Total a 6 (6.25) 0 (0.00) 0.0937
CRPC
Low 0 (0.00) 0 (0.00) d
Intermediate 0 (0.00) 0 (0.00) d
High a 1 (1.51) 0 (0.00) 0.4174
Total a 1 (1.04) 0 (0.00) 0.5017
* p < 0.05.
BCR ¼ biochemical recurrence; CRPC ¼ castration-resistant prostate cancer;
RaLRP ¼ robotic-assisted laparoscopic radical prostatectomy; RT ¼ radiotherapy.
a Chi-square test or Fisher exact test.p ¼ 0.2059; intermediate risk: 23.80% vs. 7.69%, p ¼ 0.2309; high
risk, 27.27% vs. 27.27%, p¼ 0.8428). However, among the patients in
the RT group, six developed metastatic bone disease during the 1-
year follow up, whereas none of the patients in the surgical group
developed metastatic bone disease. Overall, there was no signiﬁ-
cant difference between these two groups with regard to oncologic
control.
Of all the patients who received surgery, the 1-month early
continence rate was 65.11% (28/43 patients) and the 1-year conti-
nence rate was 90.69% (39/43 patients), with incontinence
requiring only one safety pad per day or showing only mild stress
urinary incontinence symptoms.
With regard to surgical complications in the RaLRP group, one
patient suffered from conversion during the operation (1/43 pa-
tients, 2.3%) and one patient suffered from rectal injury (1/43 pa-
tients, 2.3%). No surgical mortality was noted. In the RT group,
different complications were noted, with patients showing lower
urinary tract symptoms and bladder outlet obstruction. Among
these, 80.20% of the patients suffered from lower urinary tract
symptoms (77/96 patients) that required medication, 21.87% of the
patients suffered from bladder outlet obstruction and required
transient Foley catheter or ultrasound (21/96 patients), and 16.66%
of the patients requiring transurethral incision of the prostate or
transurethral prostatectomy (16/96 patients). One of these patients
(1.04%) required permanent suprapubic cystostomy; 28.12% (27/96)
of the patients suffered from radiation cystitis and 12.5% (12/96)
suffered from radiation proctitis (Table 4).
4. Discussion
Our analysis shows that during the 1-year follow up, patients
who received RaLRP had a “noninferior” outcome when compared
with those who received RT (all patients were aged > 75 years).
During the 1-year follow up, there was no signiﬁcant difference in
the BCR rate between the surgical group and the RT group, but this
may be due to the small sample size and the limited follow up.
However, patients who received RaLRP had early continence re-
covery and fewer lower urinary tract symptoms, and thus the
surgical group showed a good continence rate. This could correlate
to a better quality of life; however, there is still some debate
regarding these points.
4.1. Trifecta outcome
Salomon et al15 ﬁrst introduced the concept of trifecta outcome
in patients with prostate cancer receiving open, laparoscopic and
perineal radical prostatectomy. In their study, 205 patients were
Table 4
Complications and comorbidities.
RaLRP RT/HT group
Low urinary tract symptoms requiring medication 80.20% (77/96)
Bladder outlet obstruction
Foley or ultrasound 21.87% (21/96)
TUI or TURP 16.66% (16/96)
Suprapubic cystostomy 1.04% (1/96)
Radiation cystitis 28.12% (27/96)
Radiation proctitis 12.5% (12/96)
Perioperative complication
Conversion 2.3% (1/43)
Rectal injury 2.3% (1/43)
Blood transfusion 4.6% (2/43)
Postoperative complication
Stress urinary incontinence 34.88% (15/43)
Incontinence requiring >1 pad/d 9.3% (4/43)
HT ¼ hormone therapy; RaLRP ¼ robotic-assisted laparoscopic radical prostatectomy; RT ¼ radiotherapy; TURP ¼ transurethral prostatec-
tomy; TUI ¼ transurethral incision of the prostate.
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the patients were free of BCR and had complete continence and
potency.
Subsequently, this concept was widely used in the evaluation of
patients who received radical prostatectomy. Bianco et al16 evalu-
ated 758 patients who received radical prostatectomy by applying
the trifecta concept and at 2-year follow up, 60% of patients were
found to be potent, continent, and free of cancer. Pierorazio et al17
evaluated trifecta outcomes among 406 patients who underwent
open radical prostatectomy, and reported the following rates: 72.6%
for low-risk, 58.1% for intermediate-risk, and 40.0% for high-risk
patients.
Previous studies have also clariﬁed that RaLRP can offer excel-
lent trifecta outcome. Patel et al6 reported that among 1100 pa-
tients who received RaLRP, excellent trifecta outcomes were
achieved, with 86% trifecta rate at 1 year. Moreover, for patients in
the age groups of 55 years, 55e65 years, and >65 years, there was
no signiﬁcant difference. Furthermore, “pentafecta” could be ach-
ieved among patients receiving RaLRP with a reduced early
complication rate and positive surgical margin rate.18 Ou et al7
classiﬁed patients according to the D'Amico criteria, and demon-
strated that RaLRP offered a feasible outcome among high-risk
patients. In their study, among the 300 patients enrolled, the pos-
itive surgical margin and positive lymph node metastasis rate
increased with the increasing risk of cases and the BCR rate was
3.1%, 11.36%, and 19.59% in the low-, intermediate-, and high-risk
groups, respectively. In consideration of the beneﬁts of RaLRP, Hu
et al19 carried out a retrospective observational study of 5556
RaLRP and 7878 open radical prostatectomy cases from 2004 to
2009 from Surveillance Epidemiology and End ResultseMedicare
linked data. Their study results showed that RaLRP was associated
with fewer positive margins and better early cancer control within
24 months of surgery.
In the present study, we emphasized the 1-year continence rate
and biochemical failure rate. However, we did not consider the
potency rate because of the old age of our patients (all aged > 75
years), and also because the level of sexual function and libidowere
not as important as oncologic control and quality of life.
4.2. RaLRP and age
A previous study has shown that RaLRP could offer good onco-
logic control, complete continence, potency, fewer surgical com-
plications, and less surgical margins.18 Thus, we wanted to validate
the effectiveness of this procedure in an elderly patient group in
whom it may not be feasible to perform open radical prostatectomy
due to concerns related to short life expectancy (<10 years).Mendiola et al20 presented an age-stratiﬁed prospective
assessment of urinary and sexual function of 300 patients after
robot-assisted laparoscopic prostatectomy. Health-related quality
of life questionnaires were used and the patients were classiﬁed
into age groups of <50 years, 50e59 years, and 60 years. Younger
men were likely have an early recovery of continence and potency,
however, continence outcomes were equal in each group of pa-
tients after a 1-year follow up.
It has to be noted that these studies were restricted to patients
younger than 70 years, because older patients were historically not
suitable for radical prostatectomy due to their shorter life expec-
tancy and poor functional outcomes. However, during the past 3
decades, overall mortality related to heart disease has decreased by
a quarter, whereas cancer-related mortality has grown by a similar
increment.20 Shikanov et al21 clariﬁed that patients older than 75
years receiving RaLRP could fulﬁll requirements to achieve a good
continence rate after 1-year follow up.
According to our results, patients could achieve a 1-year conti-
nence rate of up to 72.09% (31/43 patients), which is excellent in
comparison with previous studies.20,22
Multiple factors may affect continence and potency after radical
prostatectomy such as baseline status, surgical technique, extent of
nerve sparing, and adjuvant or salvage therapy. The anatomic
components supporting the continence mechanism, especially the
puboprostatic collar (puboprostatic ligaments, arcus tendineus, and
puboperinealis muscle), are usually spared to improve continence
recovery.13 A previous study has demonstrated the impact of
modiﬁed posterior reconstruction of the rhabdosphincter on early
recovery of continence and anastomotic leakage rates after robot-
assisted radical prostatectomy.14
4.3. RaLRP and radiotherapy
Traditionally, external beam radiotherapy (EBRT) is considered a
local treatment for patients with prostate cancer over the age of 70
or those having a life expectancy <10 years. Systemic treatment
would be considered in patients in the high-risk group. Further-
more, with advances in our knowledge on pelvic anatomy, surgical
techniques, and analgesics, invasive surgical intervention has been
shown to have greater acceptance.
Sun et al23 compared the efﬁcacy between radical prostatec-
tomy, RT, and observation in patients with clinically localized
prostate cancer and showed that there was a survival beneﬁt
among those in the surgical group. However, there was no signiﬁ-
cant difference in patients with a life expectancy of <10 years
among these three groups. Furthermore, Boorjian et al24 studied
long-term survival among patients with high-risk prostate cancer.
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tectomy (RRP) and 609 patients received EBRT (with or without
ADT). The authors concluded that RRP alone and EBRT plus ADT
provided similar long-term cancer control in patients with high-
risk prostate cancer.
Regarding functional results, it has been shown that patients
undergoing EBRT or brachytherapy have better short-term conti-
nence and potency outcomes compared with RP, but at the expense
of worse rectal and irritative urinary symptoms.25
In conclusion, radical prostatectomy could offer better oncologic
outcome than RT in selective patients and RT is recommended for
patients with a short life expectancy or metastasis disease. With
regard to our study group, all patients in the RT group received
intensity-modulated radiation therapy and doses 72 cGy. How-
ever, among the intermediate- and high-risk patients, hormone
therapy with ADTwas administered as a systemic treatment, which
may result in some bias in oncologic outcome when surgical
intervention was considered as “local treatment.” Furthermore,
concerning quality of life, the RT group seems to be suffering from
more lower urinary tract symptoms, which may need medication
or surgical intervention. Radiation cystitis and proctitis appear to
be common in this group of patients. Thus, we observed that RaLRP
could be a noninferior management in patients aged >75 years
with regard to continence outcomes.
However, this study has a number of limitations that should be
highlighted. First, the 1-year follow up may be too short to clarify
any differences and any oncology control beneﬁt. Prior analysis has
indicated that biochemical evidence (PSA levels) of recurrence
usually precedes clinical metastases by a mean of approximately 8
years and cancer-speciﬁc mortality by a mean of approximately 13
years.26 One-year biochemical failure may be related to disease per
se not to the treatment modalities. Second, in our study, we used
PSA  0.2 ng/mL as the threshold of biochemical failure in the
surgical group and the deﬁnition of biochemical failure in the RT
group was nadir þ 2 ng/mL. However, these deﬁnitions are neither
intended nor able to allow for comparisons between the two
groups because the surgical deﬁnition will identify recurrence
approximately 5 years earlier than the radiation deﬁnition.27 This
may put these two comparative groups into an imbalanced base-
line, and thus overall survival or disease-speciﬁc survival may be
more suitable comparative parameters for these two groups. Be-
sides, the limited follow-up duration (1 year) may also limit this
comparison. Third, it is difﬁcult to compare these two groups of
patients with regard to functional outcome or comorbidity because
they are in different starting lines.
Therefore, further study concerning survival beneﬁt with long-
term follow up or with some objective scale such as health-
related quality of life may offer more reliable results.
5. Conclusion
Our study results show that in patients >75 years old with
prostate cancer, RaLRP appears to be a “noninferior” management
in comparison with RT plus ADT. However, we failed to identify
reliable differences because of the limited follow-up duration
(1 year). It is also difﬁcult to suggest whether the surgical group
shows better functional outcomes. However, we could conﬁrm that
despite the old age of the patients, RaLRP offers a good 1-year
continence outcome.
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